Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi

[cafead]

via Eli Lilly has held the grand reveal of the Alzheimer’s disease trial data it hopes will secure FDA approval for donanemab by the end of the year. The update shows improvements over placebo continued to grow over the course of the study, even after patients stopped taking the drug, but confirmed concerns about safety and the value of treating patients early.

article source